Navigation Links
ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report
Date:2/2/2010

DALLAS, Texas, February 2 /PRNewswire/ -- ReportsandReports announce to have Biosimilars Series: Forecast Analysis (http://www.reportsandreports.com/market-reports/biosimilars-series-Forecast- Analysis/) Market Research Report in its store

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

    Scope

    - Molecule-specific forecasts for biosimilar epoetin alpha, filgrastim,
      interferon beta, interferon alpha, human growth hormone, and
      insulin-glargine.

    - Molecule-specific forecasts for France, Germany, Italy, Spain, the US,
      and Japan through 2019.

    - An overview of the emerging biosimilars market, including a regulatory
      update.

    - An outline of the key issues which will impact on biosimilars uptake
      going forward.

Highlights

As the first to introduce guidelines for biosimilar drug approval, Europe has emerged as the testing ground for biosimilar drugs, with biosimilars for three biologics having entered the market to date human growth hormone, epoetin alpha, and filgrastim.

The size of the US market, combined with the voracious generic erosion that characterize it, make it an attractive prospect for would-be biosimilars makers, and as such, it represents the real prize, contingent on the creation of a biosimilars approval pathway.

Although guidance for biosimilar approval was issued in Japan in 2009, this market is unlikely to experience significant biosimilar incursion through the forecast period, contributing at most 1% to total seven major market volume sales in 2019.

    Reasons to Purchase

    - Learn how biosimilar uptake for six biologic drugs is anticipated to
      change through 2019, in France, Germany, Italy, Spain, the UK, the US,
      and Japan.

    - Understand how the seven major markets compare in terms of speed and
      extent of biosimilars uptake.

    - Identify the key molecule and market specific drivers and resistors to
      biosimilar uptake.

Related Reports

HVAC in the U.S., 2nd Edition - Green and Global ( http://www.reportsandreports.com/market-reports/hvac-in-the-us-2nd-edition-%E 2%80%94-green-and-global/)

Global Biomaterial Market (2009-2014) ( http://www.reportsandreports.com/market-reports/global-biomaterial-market-200 9-2014/)

World Market for Biosimilars and the Potential for US Followon Biologics (http://www.reportsandreports.com/market-reports/world-market-for-biosimilars -and-the-potential-for-us-followon-bi/)

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

    Contact:

    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    http://www.reportsandreports.com/


SOURCE MarketsandMarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. BioVascular Inc. Closes $10.87 Million Series C Financing
3. PG500 Series Presented at the AACR Annual Meeting in San Diego
4. Light Sciences Oncology Raises $40.1 Million in Series C Financing
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
7. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
8. Lutonix Inc. Announces $20 Million Series B Financing
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... for the fourth quarter and year ended December 31, ... of transformational progress for Orexigen, beginning with the re-acquisition ... Commencing early March, the team at Orexigen demonstrated remarkable ... which reshaped and strengthened our Company while rewarding us ...
(Date:3/28/2017)... and TORONTO , March ... leading full service medical device development firm, ... the visionary Toronto -based medical device ... will better serve medtech companies throughout North ... resources and experienced medical device talent spanning the design, ...
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is pleased to be invited to the Siemens Healthineers annual customer education symposium, ... The event will take place from March 27 - 31, 2017 at the ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... ... process management software and services, is proud to announce it has joined the ... professional association representing the interests of chronically ill, disabled, and dying Americans of ...
(Date:3/28/2017)... ... ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; Dr. ... will speak to the press on behalf of over 200 doctors, scientists, and scientific ... commission. , WHERE: , Zenger Room, National Press Club, 529 14th Street NW, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... relocated its corporate headquarters to a new, more expansive office space in order ... 2016, Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
Breaking Medicine News(10 mins):